Mark A. Weinberger, a director at Johnson & Johnson (NYSE:JNJ), recently acquired 1,000 shares of the company's common stock. The shares were purchased at a price of $147.22 each, amounting to a total transaction value of $147,220. This acquisition increases Weinberger's direct ownership to 1,000 shares. The transaction was disclosed in a filing with the Securities and Exchange Commission, dated December 12, 2024. InvestingPro subscribers can access 8 additional key insights about JNJ, including detailed insider trading patterns and comprehensive valuation metrics through the Pro Research Report, available for over 1,400 US stocks.
In other recent news, Johnson & Johnson has been the focus of several significant developments. The company has reported a sturdy Q3 performance with operational sales growth of 6.3%, reaching $22.5 billion. Following this financial performance, RBC (TSX:RY) Capital Markets and Stifel Financial (NYSE:SF) have upgraded their ratings for the company.
In the pharmaceutical sector, Johnson & Johnson has submitted applications to the FDA for the use of its drug TREMFYA® in treating children with specific conditions and for a new subcutaneous induction regimen of TREMFYA® for adults with moderately to severely active ulcerative colitis. Additionally, the FDA has awarded a second Breakthrough Therapy designation to nipocalimab, a drug developed by Johnson & Johnson, for the treatment of Sjögren's disease.
On the legal front, Johnson & Johnson is currently navigating a pause on baby powder lawsuits until mid-March due to bankruptcy trial plans, as it seeks a resolution to tens of thousands of cancer-related claims. These are some of the recent developments surrounding Johnson & Johnson.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.